logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

Press Releases

Navigation Toggle Navigation
  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Jul 27, 2020

PharmaCyte Biotech Announces Submission of Drug Master File to FDA for Company’s Pancreatic Cancer Therapy

  • Jul 13, 2020

PharmaCyte Biotech Successfully Completes Container Closure Integrity Test

  • Jul 8, 2020

PharmaCyte Biotech Successfully Completes Three-Month Stability Study

  • Jun 23, 2020

PharmaCyte Biotech Provides IND Submission Update for Pancreatic Cancer Clinical Trial

  • Jun 15, 2020

PharmaCyte Biotech Successfully Accelerates Development of Container Closure Integrity Test for Pancreatic Cancer Clinical Trial Product

  • Jun 10, 2020

PharmaCyte Biotech Successfully Develops “Change History” for its Clinical Trial Product for Pancreatic Cancer

  • Jun 8, 2020

PharmaCyte Biotech Completes Final cGMP Audit of Manufacturing Facility for Pancreatic Cancer Clinical Trial Product

  • May 26, 2020

PharmaCyte Biotech Announces Final Major Study for IND Submission Has Begun

  • May 11, 2020

PharmaCyte Biotech Conducting Final Audit of Manufacturing Facility after Batch Records Deemed cGMP Compliant

  • May 6, 2020

PharmaCyte Biotech Receives Medical Devices Registration and Submits Pre-EUA Application to the FDA for COVID-19 Diagnostic Kit

RSS
  • « Previous
  • 1...
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • ...29
  • Next »

Contact Us

PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value October 7, 2022
  • PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital August 15, 2022